Skip to main content
. 2022 Mar 2;12:848952. doi: 10.3389/fonc.2022.848952

Figure 1.

Figure 1

ZDQ-0620 inhibits the viability and proliferative ability of carcinoma cells. (A) The structure of compound ZDQ-0620. (B) The viability of HCT116, SW-480, MCF-7, and MDA-MB-231 cells treated with various concentrations of ZDQ-0620 at 24, 48, and 72 h was determined by sulforhodamine B (SRB) assay. (C) A SRB assay was also used to determine the cytotoxicity of ZDQ-0620 toward normal cell lines (HUVEC and HL7702) at 72). (D–H) The inhibitory effect of ZDQ-0620 on the growth of HCT116 cells was measured by a colony formation assay (D), LDH assay (F), and tumor sphere formation assay (G). Panel (E) the quantitative results of the colony formation assay. Panel (H) the quantitative results of the tumor sphere formation assay. Each value is the mean (± SD) from triplicate samples; # p < 0.05 vs. the control; *p < 0.05, **p < 0.01, ***p < 0.001 vs. the control. One-way analysis of variance followed by Tukey’s post hoc multiple-comparisons test.